Mymetics Corp (MYMX)

[bow-tie]

PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
March 26, 2020 04:12 ET | Source: PCI Biotech Holding ASA

https://www.globenewswire.com/news-release/2020/03/26/2006763/0/en/PCI-Biotech-US-patent-for-the-vaccine-technology-fimaVacc-with-a-new-important-class-of-adjuvants.html

The fimaVacc programme aims to enhance the cellular immune responses that are important for the therapeutic effect of vaccines, and the fimaVacc technology has proven excellent preclinical efficacy with protein- and peptide-based vaccines. The technology has shown particularly strong CD8 T-cell immune responses, which are important for therapeutic vaccination, as well as enhanced helper (CD4) T-cell and antibody responses.

https://www.mjzanon.com/brazilian-ip-news/pci-biotech-us-patent-granted-for-the-vaccine-technology-fimavacc-in-combination-with-cytokines/